Literature DB >> 18549895

T4 sympathectomy for palmar hyperhidrosis: looking for the right operation.

Tarek Mahdy1, Tamer Youssef, Hesham Abd Elmonem, Waleed Omar, Atef Abd Elateef.   

Abstract

Most surgeons still perform T2 or T2-3 sympathectomy for palmar hyperhidrosis (PH), but both of these treatments can cause severe side effects. Some recent articles advocating T4 sympathectomy have obtained satisfactory results. The aim of this study was to compare the outcomes of 3 different levels of sympathectomy. Between July 2003 and July 2006, we treated 60 patients (20 men and 40 women, mean age 26 years) who suffer from palmar hyperhidrosis by endoscopic thoracic sympathectomy (ETS). Patients were divided into 3 groups according to the level of sympathectomy: ETS2, ETS3, and ETS4 (20 patients in each group). Data were collected by review of medical charts, outpatient clinic notes, and telephone interviews. Patients were asked whether they considered their symptoms to be "cured" or "unchanged." The degree of hand dryness was assessed subjectively. Postoperative complications (wound infection, chest pain, and Horner's syndrome) were assessed. Any occurrence of gustatory sweating, rhinitis, presence and region of reflex compensatory sweating, and recurrence was noted. Patient satisfaction was assessed. Treatment success at follow-up was 90% for the ETS2, 95% for ETS3 patients, and 100% for the ETS4 patients. In the ETS2 and ETS3 groups, a higher rate of overdryness of limbs was observed (35% and 20%, respectively). The compensatory sweating was mild in the ETS4 group, whereas moderate-to-severe reflex sweating was more common in the ETS2 and ETS3 groups. About 40% of ETS2 groups and 25% of ETS3 group patients were unsatisfied with their operation. All patients of the ETS4 group were satisfied with the outcome. In conclusion, ETS4 sympathectomy is an effective method for treating PH and it decreases the rate of compensatory hydrosis (CH).

Entities:  

Mesh:

Year:  2008        PMID: 18549895     DOI: 10.1016/j.surg.2008.01.007

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Sympathicotomy for palmar hyperhidrosis: the association between intraoperative palm temperature change and the curative effect.

Authors:  Yanguo Liu; Hao Li; Xia Zheng; Xiao Li; Jianfeng Li; Guanchao Jiang; Jun Wang
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-06-02       Impact factor: 1.520

2.  Reply to: doi:10.1007/s00464-013-2987-3: re: optimization of sympathectomy to treat palmar hyperhidrosis.

Authors:  Bo Deng
Journal:  Surg Endosc       Date:  2013-05-04       Impact factor: 4.584

Review 3.  Optimal targeting of sympathetic chain levels for treatment of palmar hyperhidrosis: an updated systematic review.

Authors:  Hai-Wei Sang; Guo-Liang Li; Peng Xiong; Ming-Chuang Zhu; Min Zhu
Journal:  Surg Endosc       Date:  2017-04-07       Impact factor: 4.584

4.  A long-term evaluation of postoperative moist hands after R4/R4+5 sympathectomy for primary palmar hyperhidrosis.

Authors:  Wenhan Weng; Yanguo Liu; Jianfeng Li; Guanchao Jiang; Jun Liu; Jun Wang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 5.  Compensatory sweating after restricting or lowering the level of sympathectomy: a systematic review and meta-analysis.

Authors:  Song-Wang Cai; Ning Shen; Dong-Xia Li; Bo Wei; Jun An; Jun-Hang Zhang
Journal:  Clinics (Sao Paulo)       Date:  2015-03-01       Impact factor: 2.365

Review 6.  A systematic review and meta-analysis of T2, T3 or T4, to evaluate the best denervation level for palmar hyperhidrosis.

Authors:  Wenxiong Zhang; Dongliang Yu; Yiping Wei; Jianjun Xu; Xiaoqiang Zhang
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

7.  T3 versus T4 video-assisted thoracoscopic sympathectomy for palmar hyperhidrosis: A protocol for a systematic review and meta-analysis.

Authors:  Sui Chen; Peipei Zhang; Tianci Chai; Zhimin Shen; Mingqiang Kang; Jiangbo Lin
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.